RxDoctor Payments Data

Lea Harracksingh, MD

Internal Medicine · Plantation, FLNPI 1679560007

Payments from drug & device makers

$3,988in general payments, 2019–2025

Across 225 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$711
  • AstraZeneca$531
  • Boehringer Ingelheim$335
  • Sanofi-aventis U.S. LLC$311
  • Lilly USA, LLC$277
  • Merck$269
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$3,977100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,988 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$8,244
Medicare patients
25
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$28,397
JardianceEmpagliflozin35$18,709
ArexvyRsvpref3 Antigen/As01e/Pf98$14,406
ShingrixVaricella-Zoster Ge/As01b/Pf60$12,000
OzempicSemaglutide12$10,186
TradjentaLinagliptin11$9,142
PradaxaDabigatran Etexilate Mesylate17$5,043
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$4,709
Sitagliptin18$4,456
Insulin Glargine-Yfgn27$3,725
Wixela InhubFluticasone Propion/Salmeterol37$3,400
Atorvastatin Calcium285$3,327
Losartan Potassium203$2,226
Amlodipine Besylate186$1,959
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf31$1,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Pradaxa, Stiolto Respimat$335$37,60477 claims
PfizerEliquis$169$28,39724 claims
GSKArexvy, Shingrix$49$26,406158 claims
Novo NordiskOzempic$711$10,18612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →